Optimal Control of Acute Cisplatin-lnduced Emesis

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 56-64

  Verweij, Jaap ^a   de Wit, Ronald ^a   de Mulder, Pieter H M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 HT3 antagonists; Antiemetics; Chemotherapy related emesis; Cisplatin induced emesis

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; GRANISETRON; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; TETRAHYDROCANNABINOL; TROPISETRON;

AKATHISIA; ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DOPAMINE ANTAGONISTS; HUMANS; METOCLOPRAMIDE; NAUSEA; RANDOMIZED CONTROLLED TRIALS; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0029816125     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227642     Document Type: Article

References (80)

1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MHN: On the receiving end: Patients’ perception of the side cffccts of canccr chemotherapy, Eur J Cancer Clin Oncol 1983;19:203-208.
2. De Boer M, Djontono J, Visser B: Patient perception of the side effects of chemotherapy: The influence of the introduction of 5HT? antagonists, Eur J Canccr 1993;(29A suppl 6):264.
3. Seynaeve C, de Mulder PHM, Verweij J, Gralla RJ: Controlling cancer chemotherapy-induced emesis: An update, Pharm Weekbl (Sci) 1991; 13:189-197.
4. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paulc B, Pacs D, Bons J: Comparison of the 5-hydroxytrypta-mine, (serotonin) antagonist ondansetron (GR 38032F) with high-dosc mctoclopramidc in the control of cisplatin-induccd emesis, N Engl J Med 1990;322:816-821.
5. De Mulder PHM, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Lane All-man E, Beranek P, Verweij J: Ondansetron compared with high-dosc metoclopramidc in prophylaxis of acute and delayed cisplatin-induccd nausea and vomiting, Ann Intern Med 1990:113:834-840.
6. Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchckmcdyian NS, Chang A, Galvin D, Hart NE: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cy-clophosphamidc based chemotherapy, Ann Intern Med 1993; 118:407-413.
7. Miner WD, Sanger G: Inhibition of cisplatin-induced vomiting by selective 5-hvdroxytryp-tamine M-reccptor antagonism, Br J Pharmacol 1986;88:497-499.
8. Gralla RJ, Itri LM, Pisko SE, Squillantc AE, Kelsen DP, Braun DW, Bordtn LA, Braun TJ, Young CW: Anticmetic efficacy of high-dose metoclopramide: Randomised trials with placebo and prochlorperazine in pat icnts with che-motherapy-induced nausea and vomiting, N Engl J Med 1981;305:905-909.
9. Craig JB, Powell BL: Review: The management of nausea and vomiting in clinical oncology, Am J Med Sci 1987;293:34-44.
10. Grunbcrg SM, Gala KV, Lampenfield M, Jamin D, Johnson K, Cariffe P, Strych D, Krailo M: Comparison of the antiemetic efficacy of high-dose intravenous metoclopramide and high-dose intravenous halopcridol in randomized double-blind crossover study, J Clin Oncol 1984:2:782-787.
11. Sailer R, Hellcnbrecht D: High doses of metoclopramide or droperidol in the prevention of cisplatin induced emesis, Eur J Cancer Clin Oncol 1986,22:22:1199-1203.
12. Basurto C, Roila F, Del Favero A: A prospective randomised double blind crossover study comparing the antiemetic effect of alizapride and metoclopramide in patients receiving cisplatin chemotherapy, Cancer Invest 1988:475-479.
13. Sailer R, Hellenbrecht D: Comparison of the antiemetic efficacy of 2 high-dose benzamides, metoclopramidc and alizapride, against cisplatin induced emesis, CancerTreat Rep 1985:69: 1301-1302.
14. Frustaci S, Grattoni E, Tumolo S, Crivcllari D, Figoli F, Galligioni E, Veronesi A, Tirelli U, Grigoletto E: Randomised crossover antiemetic study in cisplatin treated patients, Cancer Chemoth Pharmac 1986:17:75-79.
15. Meyer BR, Levin M, Draper DE, Pasmanticr M, Lonski L, Reidenberg MM: Optimising metoclopramidc control of cisplatin induced emesis, Ann Intern Med 1984:100:393-395.
16. Kerr PJ, Graham J, McGovern E, Kclman AW, Cunningham D, Kaye SB: The relationship between steady state mctoclopramide levels and control of emesis during treatment with cispla-tinum, Br J Clin Pharm 1985;20:426-427.
17. McDcrmed JE, Cohen JL, Joseph C, Strum SB: Clinical pharmacokinetics of high-dose metoclopramide in canccr patients receiving cisplatin therapy, J Clin Oncol 1985;3:1400-1408.
18. Grunberg SM, McDcrmcd JE, Berstein L, Cohen JL: Examination of the correlation of serum MCP levels with antiemetic efficacy in patients receiving cisplatin, Canccr Chcmothcr Pharmacol 1987;20:332-336.
19. Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S: Anticmetic control and prevention of side cffccts of anticancer therapy with lora-zepam when used in combination with metoclopramide and dexamethasone, Cancer 1987; 60:2816-2822.
20. Clark RA, Gralla RJ, Kris MCI, Tyson I.B: Exploring very high dose of MCP (4-6 mg/kg): preservation of efficacy and safety with only one single dose in a combination anti-emetic regimen, Proc ASCO 1989:8:330.
21. Warrington PS, Allan SG, Cornblect MA, Mac-Phcrson JS, Smyth JF, Leonard RCF: Optimising antiemesis in canccr chemotherapy: Efficacy of continuous versus intermittent infusion of high dose mctoclopramide in emesis induced by cisplatin, Br Med J 1986:293:1334-1337.
22. Parashos PJ, Dugan WM, Fry MW: Continuous infusion metoclopramidc: Clinical trials, pharmacokinetic considerations and cost effectiveness: in Engstrom PF, Mortcnson LE, Anderson PN (eds): Progress in Clinical and Biological Research, New York, Liss, 1987, vol 248, p 303.
23. Agostinucci WA, Gannon RH, Golub GR, Martin RS, Schauer PK, Dinonno EB: Continuous infusion of metoclopramide for prevention of chemotherapy induced emesis, Clin Pharmacol 1986:5:150-153.
24. Navari RM: Comparison of intermittent versus continuous infusion mctoclopramide in control of acute nausea induced by cisplatin chemotherapy, J Clin Oncol 1989:7:943-946.
25. Tyson LB, Gralla RJ, Kris MG, Yound CW, Clark RA: Dose-ranging antiemetic trial of high-dose oral MCP, Am J Clin Oncol 1989: 239-243.
26. Anthony L, Krozcby M, Woodward N, Hains-worth JD, Handc KR, Brenner DE, Greco A, Burish TG: Anticmetic efficacy of oral versus intravenous MCP in patients receiving cisplatin, J Clin Oncol 1985;4:98-103.
27. Allan SG, Cornblcct MA, Warrington PS, Gotland IM, Leonard RC, Smyth JN: Dexametha-sone and high dose metoclopramide: Efficacy in controlling cisplatin-induccd nausea and vomiting, Br Med J 1984:289:878-879.
28. Rosell R, Abad-Esteve A, Ribas-Mundo M, Moreno I: Evaluation of a combination antiemetic regimen including IV high-dose mctoclopramide, dexamethasone, and diphenhydramine in cisplatin-based chemotherapy regimens, CancerTreat Rep 1985;69:909-910.
29. Roila F, Tonato M, Basurto C, Bella M, Passa-lacqua R, Morsia D, DiCostanzo F, Donati D, Ballatori E, Tognoni G, Franzosi MG, Del Favero A: Antiemetic activity of high dose of mctoclopramide combined with mcthvlprcdni-solone versus metoclopramidc alone in cispla-tin-treated cancer patients, J Clin Oncol 1987; 5:141-149.
30. Cognetti F, Carlini P, Pinnaro P, Ruggcri EM, Caporali C: Maintenance of antiemctic effect of a MCP/Dex combination during subsequent cisplatin courses, Oncology 1986:43:292-294.
31. Aapro MS: Present role of corticosteroids as antiemetics; in Scnn H-J, Glaus A (eds): Recent Results in Cancer Research, Berlin, Springer.1991, pp 91-100.
32. Bishop JF, Olver IN, Wolf MM, Matthews J P, Long M, Bingham J, Hillcoat BL, Cooper IA: Lorazepam: A randomised, double-blind, crossover study of a new anticmetic in patients receiving cytotoxic chemotherapy and prochlorperazine, J Clin Oncol 1984:2:691-695.
33. Gordon CJ, Pasdur R, Zicarelli A, Cummings G, Al-Sarraf M: Mctoclopramide versus mctoclopramide and lorazepam, Cancer 1989:63: 578-582.
34. Kris MG, Gralla RJ, Tyson LB, Clark RA, Kelsen DP, Reilly LK, Groshen S, Bosl GJ, Kalman LA: Improved control of cisplatin induced emesis with high-dose mctoclopramide and with combinations of mctoclopramide, dexamethasone and diphenhydramine, Cancer 1985:55:527-534.
35. Seynacvc C, Verweij J, de Molder PHM: 5-HT3 receptor antagonists, A new approach in emesis, A review of ondansetron, granisetron and tropisetron, Anticancer Drugs 1991;2: 343-355.
36. Tyers MB, Freeman AJ: Mechanism of the anticmetic activity of 5-HT3 rcceptor antagonists, Oncology 1992;49:263-268.
37. Andrews PLR, Bhandari P, Davcv PT, Bingham S, Marr HE, Blower PR: Are all 5 HT3 receptor antagonists the same? Eur J Canccr 1992;28A suppI 1:S2-S6.
38. Aapro MS: ‘Setron'?:Arc 5-HT3 receptor antagonists different? Eur J Cancer 1993;29a: 1655.
39. Kris MG, Gralla RJ, Clark RA, Tyson LB: Dose-rangning evaluation of the serotonin antagonist GR38032F when used as an antiemet-ic ir, patients receiving anticancer therapy, J Clin Oncol 1988:6:659-662.
40. Grundberg SM, Stevenson LL, Russell CA, McDermed JE: Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induccd nausea and vomiting, J Clin Oncol 1989;7:1137-1141.
41. Kris MG, Gralla RJ, Clark RA, Tyson LB: Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin, J Natl Cancer Inst 1989:81:42-46.
42. Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojastch A, Tapazoglou E, Sartiano GP, While DR, Werner K, Chubb JM: GR38032F: A novel compound effective in the prevention of acute cisplatin-induced emesis, J Clin Oncol 1989;7:700-705.
43. Khojasteh A, Sartiano G, Tapazoglou E, Gandara D, Bernard S, Finn A: Ondansetron for the prevention of emesis induced by high-dose cisplatin, Cancer 1990;66:1101-1105.
44. Hainsworth J, Harvey W, Pendergrass K, Ka-siniis B, Obion D, Monaghan G, Gandara D, Hesketh P, Khojastch A, Harker G, York M, Siddiqui T, Finn A: A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous mctoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy, J Clin Oncol 1991;9:721-728.
45. Cubcddu LX, Hoffmann IS, Fuenmayor NT, Finn AL: Efficacy of ondansetron and the role of serotonin in cisplatin-induced nausea and vomiting, N Engl J Med 1990:322:810-816.
46. Marty M, D’Allens H: Etude randomisee en double-insu comparant I'cfficacite dc I’ondan-setron scion deux modes d’administration: injection unique et perfusion continue, Cahiers Cancer 1990;2:541-546.
47. Seynaeve C, Schuller J, Buscr K, Porteder LL, Van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Paes D, de Mulder PHM: Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acutc cisplatin-induced emesis: A mul-ticcntrc, double-blind, randomised, parallel group study, BrJ Cancer 1992:66:192-197.
48. Ruff P, Paska W, Goedhals L, Pouillart P, Riviere A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R, Butcher M, Forster J, McQuade B: Ondansetron compared with granisctron in the prophylaxis of cisplatin-induced acutc emc-sis: A multicentre double-blind randomised, parallel-group study, Oncology 1994:51:113-118.
49. Beck ThM, Hesketh PJ, Madajcwicz S, Navari RM, Pendergrass K, Lester F.P, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, Brick-er LJ, Keller AM, Mortimer J, Galvin DV, House KW, Bryson JC: Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dosc regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting, J Clin Oncol 1992:10:1969-1975.
50. Upward JW, Arnold BDC, Link C, Pierce DM, Allen A, Tasker TCG: The clinical pharmacology of granisctron (BRL43694A), a novel specific 5-HT3 antagonist, Eur J Cancer 1990: 26(suppl 1):512-515.
51. Kamanabrou D, on behalf of the Granisetron Study Group: Intravenous granisetron, Establishing the optimal dose, Eur J Canccr 1992: 28A(suppl 1):S6-11.
52. Soukop M, on behalf of the Granisetron Study Group: A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin, Eur J Cancer 1990;29(suppl I):S15- S19.
53. Chcvallier B, on behalf of the Granisetron Study Group: The control of acute cisplatin-induced emesis: A comparative study of granisctron and a combination regimen of high-dose metociopramide and dexamethasone, Br J Cancer 1993:68:176-180.
54. Tyson LR, Gralla RJ, Kris MG, Clark RA: Phase I antiemetic study of the serotonin antagonist ICS 205-930, Proc Am Soc Clin Oncol 1989:8:331.
55. Stamatakis L, Michcl J, Van Belle S, Cocquyt V, Keppens C, Van Hove R, De Beider B, Roosens W: ICS 205-930: A dose finding study in the prevention of cisplatin induced nausea and vomiting, Proc Am Soc Clin Oncol 1989:8
56. Krzakowski M, Madaj G, Pawinskv A, et al: A comparative study of the use of ICS 205-930/ Navoban, A 5-HTi antagonist, versus a standard anti-emetic regimen of dcxamcthasone and metociopramide in the treatment of che-mothcrapv-induced emesis, Ann Oncol 1992: 3(suppl I):155.
57. Kris MG, Tyson LB: Tropisctron (ICS 205-930): A selective 5-hydroxtryptaminc antagonist, Eur J Canccr 1993:29A(suppl 1):30-32.
58. Roila F, Tonato M, Cognctti F, Cortesi E, Fav-alli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, Ballatri E, Del Favero A: Prevention of cisplatin-induced cmesis: A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone, J Clin Oncol 1991:9: 675-678.
59. Smith DB, Newlands ES, Rustin GJS, Bcgcnt RHJ, Howells N, McQuade B, Bagshawe KD: Comparison of ondansetron and ondansetron plus dexamethasone as anticmctic prophylaxis during cisplatin-containing chemotherapy, Lancet 1991:338:487-490.
60. Smyth JF, Coleman RE, Nicolson M, Gall-meier WM, Leonard RCF, Combleet MA, Allan SG, Upadhyaya BK, Bnmtsch U: Does dcxamcthasone enhancc control of acutc cisplatin induced cmesis by ondansetron? Br Med J 1991:303:1423-1426.
61. Italian Group for Anticmctic Research: Difference in persistence of efficacy of two antiemetic regimens on acute cmesis during cisplatin chemotherapy, J Clin Oncol 1993; 11:2396-2404.
62. Cunningham D, Hill M, Dicato M, Verweij J, Crombez R, de Mulder PHM, du Bois A, Stewart A, Smyth J, Selby P, van Straelcn D, Pari-daens R: Optimal anti-emetic therapy for cisplatin induced emesis over repeated courses, ProcASCO 1994:13:449.
63. Soukop M, McQuade B, Hunter E, Stwart A, Kaye S, Cassidy J, Kerr D, Khanna S, Smyth J, Coleman R, Cunningham D, Powels T, Davidson N, Hutchcon A, Green J, Slater A, Rustin G, Carney D: Ondansetron compared with metociopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer, Oncology 1992;49:295-304.
64. Blijham GH: Does granisctron remain effective over multiple cycles? Eur J Canccr 1992; 28A(Sl):sl7-s21.
65. Sorbc B: Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: The Nordic experience, Ann Oncol 1993: 4(suppl 3):s39-s42.
66. Wet de M, Falkson G, Rapoport BL: Repeated use of granisctron in patients receiving cytostatic agents, Cancer 1993:74:4043-4049.
67. de Wit R, Schmitz PHM, Verweij J, Boer de-Dennert M, Mulder dc PHM, Planting AST, Burg van der MEL, Stoter G: Analysis of cumulative probabilities shows that the efficacy of 5-HTi antagonist prophylaxis is not maintained, J Clin Oncol 1996:14:644-651.
68. Einhorn LH, Naggy C, Werner K, Finn AL: Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy, J Clin Oncol 1990:8:731-735.
69. Hainsworth JD: The use of ondansetron in patients receiving multiplc-day cisplatin regimens, Semin Oncol 1992:19(suppl 10):48-52.
70. Sledge GW, Einhorn LH, Nagy C, House K: Phase III double-blind comparison of intravenous ondansetron and metociopramide as an-ticmctic therapy for patients receiving multi-ple-day cisplatin-based chemotherapy, Cancer 1992:70:2524-2528.
71. Fox SM, Einhorn LH, Cox E, Powell N, Abdv H: Ondansetron versus ondansetron, dexamethasone, and chlorpromazinc in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy, J Clin Oncol 1993:11:2391-2395.
72. Rath U, Upadhyaya BK, Arechavala E, Bock-mann H, Dearnaley D, Droz JP, Fossa SD, Henriksson R, Aulitzky WE, Jones WG, Wciss-bach L, Paska W, Freeman A: Role of ondansetron plus dexamethasone in fractionated chemotherapy, Oncology 1993:50:168-172.
73. Bremer K on behalf of the Granisctron Study Group: A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapridc plus dexamethasone in the prophylaxis and control of eniesis in patients receiving 5-day cytostatic therapy, Eur J Cancer 1992:28:1018-1022.
74. Pellicr P, Dilly SG, Friedman C, Yocom K: Crossover analysis of efficacy and side effects of granisctron and ondansetron, Proc ASCO 1994:13:441.
75. Mantovani G, Maccio A, Currelli L, Bianchi A, Gebbia V, Testa A: Comparison of the effectiveness of three 5HTj-receptor antagonists in the prophylaxis of acutc vomiting induced by highly cmetogenic chemotherapy (high-dose cisplatin) for the treatment of primary head and neck cancer, ProcASCO 1994; 13:428.
76. Martoni A, Angelclli B, Guaraldi M, Strocchi E, Pannuti F: Granisctron vs, Ondansetron in the prevention of cisplatinum-induced emesis: An open randomized cross-over study, Proc ASCO 1994:13:431.
77. Smith RN: Safety of ondansetron, Eur J Cancer Clin Oncol 1989:25(suppl 1):S47-S50.
78. Plosker GL, Goa KL: Granisetron: A review of its pharmacological properties and therapeutic use as an anticmctic, Drugs 1991:42:805-824.
79. de Bruijn KM: Tropisctron: A review of the clinical experience, Drugs 1992:43:11-22.
80. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P: Ondansetron plus me-topimazine compared wtih ondansetron alone in patients receiving moderately cmetogenic chemotherapy, N Engl J Med 1993:328:1076- 1081.